Encompass Health Co. (NYSE:EHC) Position Trimmed by Financial Life Advisors

Financial Life Advisors decreased its holdings in shares of Encompass Health Co. (NYSE:EHC) by 8.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,684 shares of the company’s stock after selling 805 shares during the period. Financial Life Advisors’ holdings in Encompass Health were worth $717,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in EHC. Benjamin Edwards Inc. boosted its holdings in shares of Encompass Health by 3.8% during the fourth quarter. Benjamin Edwards Inc. now owns 3,885 shares of the company’s stock valued at $259,000 after acquiring an additional 142 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Encompass Health by 31.9% during the first quarter. GAMMA Investing LLC now owns 616 shares of the company’s stock valued at $51,000 after acquiring an additional 149 shares during the period. Treasurer of the State of North Carolina boosted its holdings in shares of Encompass Health by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 48,339 shares of the company’s stock valued at $3,246,000 after acquiring an additional 231 shares during the period. Linden Thomas Advisory Services LLC boosted its holdings in shares of Encompass Health by 1.7% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 15,473 shares of the company’s stock valued at $1,032,000 after acquiring an additional 253 shares during the period. Finally, Handelsbanken Fonder AB boosted its holdings in shares of Encompass Health by 1.9% during the fourth quarter. Handelsbanken Fonder AB now owns 15,953 shares of the company’s stock valued at $1,064,000 after acquiring an additional 300 shares during the period. Institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Up 0.2 %

NYSE EHC traded up $0.14 on Monday, hitting $85.93. 483,469 shares of the company were exchanged, compared to its average volume of 633,193. The company’s 50 day moving average price is $84.77 and its 200-day moving average price is $77.58. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.37. The firm has a market capitalization of $8.65 billion, a P/E ratio of 23.23, a price-to-earnings-growth ratio of 1.34 and a beta of 0.89. Encompass Health Co. has a twelve month low of $57.55 and a twelve month high of $87.94.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.19. The firm had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.27 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.88 EPS. Analysts predict that Encompass Health Co. will post 4.1 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be issued a $0.15 dividend. The ex-dividend date is Monday, July 1st. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.70%. Encompass Health’s dividend payout ratio is 16.22%.

Wall Street Analyst Weigh In

EHC has been the subject of several research analyst reports. Stephens reaffirmed an “overweight” rating and issued a $94.00 price objective on shares of Encompass Health in a report on Wednesday, June 5th. Mizuho upped their price objective on shares of Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Raymond James reaffirmed a “strong-buy” rating and issued a $95.00 price objective (up previously from $85.00) on shares of Encompass Health in a report on Friday, April 26th. Royal Bank of Canada upped their price objective on shares of Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, May 22nd. Finally, Barclays upped their price objective on shares of Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $93.29.

Insider Activity

In other news, CEO Mark J. Tarr sold 44,976 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total value of $3,745,151.52. Following the transaction, the chief executive officer now owns 554,098 shares in the company, valued at approximately $46,139,740.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP John Patrick Darby sold 14,543 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $83.94, for a total value of $1,220,739.42. Following the transaction, the executive vice president now owns 84,773 shares in the company, valued at $7,115,845.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total value of $3,745,151.52. Following the completion of the transaction, the chief executive officer now owns 554,098 shares in the company, valued at approximately $46,139,740.46. The disclosure for this sale can be found here. Insiders have sold 69,519 shares of company stock worth $5,816,091 in the last 90 days. Company insiders own 2.10% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.